StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a research report released on Thursday morning. The firm issued a sell rating on the medical device company’s stock.
NeuroMetrix Stock Performance
NURO opened at $3.65 on Thursday. NeuroMetrix has a 1 year low of $2.70 and a 1 year high of $11.82. The stock’s 50 day simple moving average is $3.75 and its 200-day simple moving average is $3.82.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The medical device company reported ($1.43) EPS for the quarter. NeuroMetrix had a negative return on equity of 31.31% and a negative net margin of 110.64%. The business had revenue of $1.32 million for the quarter.
Hedge Funds Weigh In On NeuroMetrix
About NeuroMetrix
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.
Read More
- Five stocks we like better than NeuroMetrix
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Comprehensive PepsiCo Stock Analysis
- Stock Market Upgrades: What Are They?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.